Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02355535|
Recruitment Status : Completed
First Posted : February 4, 2015
Last Update Posted : September 24, 2020
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Solid Tumor Pancreatic Neuroendocrine Tumor Neuroendocrine Tumors||Drug: PAC-1||Phase 1|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||48 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||(STM-03) Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1|
|Actual Study Start Date :||February 2015|
|Actual Primary Completion Date :||May 18, 2020|
|Actual Study Completion Date :||May 18, 2020|
Experimental: Open label
Using a dose-escalation design, PAC-1 is administered orally on days 1-21, at the assigned dose, of a 28-day cycle.
PAC-1 is taken orally on days 1-21 of a 28-day cycle.
Other Name: Procaspase Activating Compound-1
- Maximum Tolerated Dose [ Time Frame: Up to 30 days post last dose ]The primary objective of this study component is to determine the maximum tolerated dose (MTD) of PAC-1 in patients with advanced, previously treated malignancy, by evaluation of toxicity and tolerability.
- Adverse Effects [ Time Frame: Up to 30 days post final dose ]Characterize adverse effects (AE) of PAC-1 in patients with advanced malignancy.
- Disease Response based on RECIST Criteria for patients with solid tumors [ Time Frame: Up to 8 weeks following final dose ]Evaluate clinical response of PAC-1 in patients with solid tumors (RECIST v 1.1).
- Disease Response based on Deauville PET Criteria for patients with lymphoma [ Time Frame: Up to 8 weeks following final dose ]Evaluate clinical response of PAC-1 in patients with lymphoma (Deauville PET Criteria).
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years to 85 Years (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Male or female ≥ 18 years of age
- Diagnosis of advanced solid tumor or hematologic malignancy (limited to lymphoma) that has failed or become intolerant to standard therapy
- Has measurable disease, defined as at least 1 tumor that fulfills the criteria for a target lesion according to RECIST 1.1, or lymphoma that fulfills the Deauville PET Criteria
- Has an ECOG PS of 0, 1, or 2
- Has total bilirubin < 1.5 mg/dL, serum albumin > 3.0 gm/dL, AST and ALT < 1.5 ULN or < 3 x ULN for subjects with known hepatic metastases
- Has serum creatinine < 1.5 × ULN
- Has hemoglobin ≥ 10 g/dL, ANC ≥ 1.5 × 109/L, and platelet count ≥ 100 × 109/L
- Must be able to take oral medication and to maintain a fast as required for 2 hours before and 1 hour after capsule(s) administration
- Must be willing and able to comply with study
- Has read, understood, and signed the ICF
- Women of childbearing potential must not be pregnant or breast-feeding. In addition, a medically acceptable method of birth control must be used or total abstinence. Women who are postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy, or hysterectomy) are not considered to be WOCP
- Men who are not surgically or medically sterile must agree to use an acceptable method of contraception. Male patients with female sexual partners who are pregnant, possibly pregnant, or who could become pregnant during the study must agree to use condoms at least one month after the last dose of study drug. Total abstinence for the same study period is an acceptable alternative
- Prior systemic treatments for metastatic disease are permitted but may not be ongoing, including targeted therapies, biologic response modifiers, chemotherapy, hormonal therapy, or investigational therapy
- Willingness to donate blood for biomarker studies related to the type of therapies used in this trial and the tumor types being treated
- Had surgery within 4 weeks prior to study treatment except for minor procedures (hepatic biliary stent placement is allowed)
- Gliomas are excluded, as well as any history of brain metastases, seizures or underlying brain injury
- May not have received cytotoxic chemotherapy, targeted therapies, biologic response modifiers, chemotherapy, and hormonal therapy within the last 3 weeks, or nitrosureas within the last 6 weeks prior to study treatment.
- Has a history of blood clots, pulmonary embolism, or DVT unless controlled by anticoagulant treatment
- Has a history of an arterial thromboembolic event within the prior six months including CVA, TIA, MI, or unstable angina
- Has uncontrolled HIV or hepatitis B or C
- Has any clinically significant infection
- Has any other severe, uncontrolled medical condition, including uncontrolled DM or unstable CHF
- Radiation therapy to more than 25% of the bone marrow
- Prior allogeneic bone marrow or organ transplantation
- > Grade 1 peripheral neuropathy within 14 days before enrollment.
- Patient has received other investigational drugs with 14 days before enrollment
- Other severe acute or chronic medical or psychiatric conditions or laboratory abnormality that may increase the risk associated with study participation
- Abnormalities on 12-lead electrocardiogram (ECG) considered by the investigator to be clinically significant (such as acute ischemia, left bundle branch block, ventricular arrhythmias) or baseline prolongation of the rate-corrected QT interval (e.g., repeated demonstration of QTc interval > 480 milliseconds)
- Presence of any non-healing wound, fracture, or ulcer
- Has any condition that, in the opinion of the investigator, might jeopardize the safety of the patient or interfere with protocol compliance
- Has any mental or medical condition that prevents the patient from giving informed consent
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02355535
|United States, Illinois|
|University of Illinois at Chicago|
|Chicago, Illinois, United States, 60612|
|United States, Maryland|
|Johns Hopkins Kimmel Cancer Center|
|Baltimore, Maryland, United States, 21231|
|United States, Minnesota|
|Saint Paul, Minnesota, United States, 55101|
|Principal Investigator:||Oana C Danciu, M.D.||University of Illinois at Chicago|
|Responsible Party:||Oana Danciu, MD, Assistant Professor, University of Illinois at Chicago|
|Other Study ID Numbers:||
|First Posted:||February 4, 2015 Key Record Dates|
|Last Update Posted:||September 24, 2020|
|Last Verified:||September 2020|
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue